American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome

Gastroenterology

Volumn 149, Issue 3, 2015, Pages 783e20-813.e20

  Ladabaum, Uri ^a   Ford, James M ^a   Martel, Myriam ^b   Barkun, Alan N ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; COLONOSCOPY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; FAMILY HISTORY; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; MISMATCH REPAIR; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; TASK PERFORMANCE; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DECISION SUPPORT SYSTEM; GASTROENTEROLOGY; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; PHENOTYPE; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DECISION SUPPORT TECHNIQUES; GASTROENTEROLOGY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84939863933     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.07.037     Document Type: Article

References (160)

1. E.M. Stoffel, and F. Kastrinos Familial colorectal cancer, beyond Lynch syndrome Clin Gastroenterol Hepatol 12 2014 1059 1068
2. F.M. Giardiello, J.I. Allen, J.E. Axilbund, and et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer Gastroenterology 147 2014 502 526
3. H.T. Lynch, P.M. Lynch, S.J. Lanspa, and et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications Clin Genet 76 2009 1 18
4. R. Fishel, M.K. Lescoe, M.R. Rao, and et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer Cell 75 1993 1027 1038
5. F.S. Leach, N.C. Nicolaides, N. Papadopoulos, and et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer Cell 75 1993 1215 1225
6. A. Lindblom, P. Tannergard, B. Werelius, and et al. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer Nat Genet 5 1993 279 282
7. N. Papadopoulos, N.C. Nicolaides, Y.F. Wei, and et al. Mutation of a mutL homolog in hereditary colon cancer Science 263 1994 1625 1629
8. C.E. Bronner, S.M. Baker, P.T. Morrison, and et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer Nature 368 1994 258 261
9. H.T. Lynch, and A.J. Krush Cancer family "G" revisited: 1895-1970 Cancer 27 1971 1505 1511
10. Classics in oncology. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. By Aldred Scott Warthin. 1913 CA Cancer J Clin 35 1985 348 359
11. S. Chen, W. Wang, S. Lee, and et al. Prediction of germline mutations and cancer risk in the Lynch syndrome JAMA 296 2006 1479 1487
12. Gruber SB. Lynch Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2015.
13. L. Senter, M. Clendenning, K. Sotamaa, and et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations Gastroenterology 135 2008 419 428
14. M.L. Goodenberger, B.C. Thomas, D. Riegert-Johnson, and et al. PMS2 monoallelic mutation carriers: the known unknown Genet Med 2015 Apr 9 [Epub ahead of print]
15. Y.M. Hendriks, A. Wagner, H. Morreau, and et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance Gastroenterology 127 2004 17 25
16. E. Barrow, J. Hill, and D.G. Evans Cancer risk in Lynch syndrome Fam Cancer 12 2013 229 240
17. National Comprehensive Cancer Network. About the NCCN Clinical Practice Guidelines in Oncology. 2014. https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed January 2015.
18. H.J. Jarvinen, M. Aarnio, H. Mustonen, and et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer Gastroenterology 118 2000 829 834
19. H.F. Vasen, I. Blanco, K. Aktan-Collan, and et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts Gut 62 2013 812 823
20. K.M. Schmeler, H.T. Lynch, L.M. Chen, and et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome N Engl J Med 354 2006 261 269
21. H.F. Vasen, P. Watson, J.P. Mecklin, and et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC Gastroenterology 116 1999 1453 1456
22. A. Umar, C.R. Boland, J.P. Terdiman, and et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability J Natl Cancer Inst 96 2004 261 268
23. F. Kastrinos, E.W. Steyerberg, R. Mercado, and et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history Gastroenterology 140 2011 73 81
24. J. Balmana, D.H. Stockwell, E.W. Steyerberg, and et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome JAMA 296 2006 1469 1478
25. R.A. Barnetson, A. Tenesa, S.M. Farrington, and et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer N Engl J Med 354 2006 2751 2763
26. H. Hampel, W.L. Frankel, E. Martin, and et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) N Engl J Med 352 2005 1851 1860
27. L. Moreira, F. Balaguer, N. Lindor, and et al. Identification of Lynch syndrome among patients with colorectal cancer JAMA 308 2012 1555 1565
28. L.C. Beamer, M.L. Grant, C.R. Espenschied, and et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results J Clin Oncol 30 2012 1058 1063
29. J.M. Cunningham, C.Y. Kim, E.R. Christensen, and et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas Am J Hum Genet 69 2001 780 790
30. G. Deng, I. Bell, S. Crawley, and et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer Clin Cancer Res 10 2004 191 195
31. G.E. Palomaki, M.R. McClain, S. Melillo, and et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome Genet Med 11 2009 42 65
32. Evaluation of Genomic Applications in Practice and Prevention Working Group Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 11 2009 15 20
33. J.D. Douketis, M.A. Crowther, S.S. Cherian, and et al. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery Chest 116 1999 1240 1246
34. N. Dalkey, and O. Helmer An experimental application of the Delphi method to the use of experts Manage Sci 9 1963 458 467
35. J. Jones, and D. Hunter Consensus methods for medical and health services research BMJ 311 1995 376 380
36. P.F. Whiting, A.W. Rutjes, M.E. Westwood, and et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies Ann Intern Med 155 2011 529 536
37. A.R. Jadad, R.A. Moore, D. Carroll, and et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
38. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed February 2015.
39. G.H. Guyatt, A.D. Oxman, G.E. Vist, and et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
40. A.K. Win, R.J. Macinnis, J.G. Dowty, and et al. Criteria and prediction models for mismatch repair gene mutations: a review J Med Genet 50 2013 785 793
41. O. Khan, A. Blanco, P. Conrad, and et al. Performance of Lynch syndrome predictive models in a multi-center US referral population Am J Gastroenterol 106 2011 1822 1827 quiz 1828
42. C.J. Pouchet, N. Wong, G. Chong, and et al. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers Ann Oncol 20 2009 681 688
43. J.G. Monzon, C. Cremin, L. Armstrong, and et al. Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer Int J Cancer 126 2010 930 939
44. J. Balmana, F. Balaguer, S. Castellvi-Bel, and et al. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients J Med Genet 45 2008 557 563
45. F. Kastrinos, E.W. Steyerberg, J. Balmana, and et al. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer Gut 62 2013 272 279
46. T.A. Dinh, B.I. Rosner, J.C. Atwood, and et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population Cancer Prev Res 4 2011 9 22
47. Y. Ionov, M.A. Peinado, S. Malkhosyan, and et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis Nature 363 1993 558 561
48. J. Shia Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry J Mol Diagn 10 2008 293 300
49. A.E. de Jong, M. van Puijenbroek, Y. Hendriks, and et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer Clin Cancer Res 10 2004 972 980
50. M.C. Southey, M.A. Jenkins, L. Mead, and et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer J Clin Oncol 23 2005 6524 6532
51. L.I. Overbeek, C.M. Kets, K.M. Hebeda, and et al. Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer Br J Cancer 96 2007 1605 1612
52. C.W. Toon, M.D. Walsh, A. Chou, and et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome Am J Surg Pathol 37 2013 1592 1602
53. W. Muller, L.J. Burgart, R. Krause-Paulus, and et al. The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) - results of an international collaborative study Fam Cancer 1 2001 87 92
54. T. Debniak, G. Kurzawski, B. Gorski, and et al. Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer Eur J Cancer 36 2000 49 54
55. H. Bouzourene, L. Taminelli, P. Chaubert, and et al. A cost-effective algorithm for hereditary nonpolyposis colorectal cancer detection Am J Clin Pathol 125 2006 823 831
56. E. Brazowski, P. Rozen, S. Pel, and et al. Can a gastrointestinal pathologist identify microsatellite instability in colorectal cancer with reproducibility and a high degree of specificity? Fam Cancer 11 2012 249 257
57. F. Pigatto, A. Bateman, D. Bunyan, and et al. Economic and practical factors in diagnosing HNPCC using clinical criteria, immunohistochemistry and microsatellite instability analysis Hered Cancer Clin Pract 2 2004 175 184
58. D. Ramsoekh, M.E. van Leerdam, A. Wagner, and et al. Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting J Med Genet 46 2009 745 751
59. H.L. Yan, L.Q. Hao, H.Y. Jin, and et al. Clinical features and mismatch repair genes analyses of Chinese suspected hereditary non-polyposis colorectal cancer: a cost-effective screening strategy proposal Cancer Sci 99 2008 770 780
60. C.M. Reyes, B.A. Allen, J.P. Terdiman, and et al. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness Cancer 95 2002 1848 1856
61. S.D. Ramsey, L. Clarke, R. Etzioni, and et al. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer Ann Intern Med 135 2001 577 588
62. W. Kievit, J.H. de Bruin, E.M. Adang, and et al. Cost effectiveness of a new strategy to identify HNPCC patients Gut 54 2005 97 102
63. M. Mvundura, S.D. Grosse, H. Hampel, and et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer Genet Med 12 2010 93 104
64. U. Ladabaum, G. Wang, J. Terdiman, and et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer a cost-effectiveness analysis Ann Intern Med 155 2011 69 79
65. G. Wang, M. Kuppermann, B. Kim, and et al. Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome J Oncol Pract 8 2012 e24s e30s
66. T. Snowsill, N. Huxley, M. Hoyle, and et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome Health Technol Assess 18 2014 1 406
67. T. Nagasaka, J. Rhees, M. Kloor, and et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers Cancer Res 70 2010 3098 3108
68. L. Moreira, J. Munoz, M. Cuatrecasas, and et al. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer Cancer 121 2015 1395 1404
69. L. Perez-Carbonell, C. Alenda, A. Paya, and et al. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome J Mol Diagn 12 2010 498 504
70. M. Gausachs, P. Mur, J. Corral, and et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study Eur J Hum Genet 20 2012 762 768
71. X. Bessa, B. Balleste, M. Andreu, and et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening Clin Gastroenterol Hepatol 6 2008 206 214
72. S. Benlloch, A. Paya, C. Alenda, and et al. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology J Mol Diagn 8 2006 540 543
73. T. Muto, H.J. Bussey, and B.C. Morson The evolution of cancer of the colon and rectum Cancer 36 1975 2251 2270
74. D.C. Snover Update on the serrated pathway to colorectal carcinoma Hum Pathol 42 2011 1 10
75. S.J. Stryker, B.G. Wolff, C.E. Culp, and et al. Natural history of untreated colonic polyps Gastroenterology 93 1987 1009 1013
76. O. Kronborg, C. Fenger, J. Olsen, and et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test Lancet 348 1996 1467 1471
77. J.D. Hardcastle, J.O. Chamberlain, M.H. Robinson, and et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer Lancet 348 1996 1472 1477
78. E. Lindholm, H. Brevinge, and E. Haglind Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer Br J Surg 95 2008 1029 1036
79. J.S. Mandel, J.H. Bond, T.R. Church, and et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study N Engl J Med 328 1993 1365 1371
80. W.S. Atkin, R. Edwards, I. Kralj-Hans, and et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial Lancet 375 2010 1624 1633
81. N. Segnan, P. Armaroli, L. Bonelli, and et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial - SCORE J Natl Cancer Inst 103 2011 1310 1322
82. R.E. Schoen, P.F. Pinsky, J.L. Weissfeld, and et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy N Engl J Med 366 2012 2345 2357
83. S.J. Winawer, A.G. Zauber, M.N. Ho, and et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup N Engl J Med 329 1993 1977 1981
84. A.G. Zauber, S.J. Winawer, M.J. O'Brien, and et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths N Engl J Med 366 2012 687 696
85. A. Arrigoni, T. Sprujevnik, V. Alvisi, and et al. Clinical identification and long-term surveillance of 22 hereditary non-polyposis colon cancer Italian families Eur J Gastroenterol Hepatol 17 2005 213 219
86. M. Jablonska, L. Reznikova, J. Kotrlik, and et al. Clinical implications of recognition of the hereditary non-polyposis colon cancer syndrome (HNPCC) for the early detection of colorectal cancer Sb Lek 96 1995 275 282
87. H.J. Jarvinen, J.P. Mecklin, and P. Sistonen Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer Gastroenterology 108 1995 1405 1411
88. D.A. Stupart, P.A. Goldberg, U. Algar, and et al. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation Colorectal Dis 11 2009 126 130
89. S. Stuckless, J.S. Green, M. Morgenstern, and et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation Clin Genet 82 2012 439 445
90. S.J. Lanspa, H.T. Lynch, T.C. Smyrk, and et al. Colorectal adenomas in the Lynch syndromes. Results of a colonoscopy screening program Gastroenterology 98 1990 1117 1122
91. S.V. Hodgson, C. Harocopos, and P. Gaglia Screening results in a family cancer clinic: five years experience Anticancer Res 13 1993 2581 2585
92. J.P. Mecklin, M. Aarnio, E. Laara, and et al. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome Gastroenterology 133 2007 1093 1098
93. I. Dove-Edwin, A.E. de Jong, J. Adams, and et al. Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without Lynch syndrome Gastroenterology 130 2006 1995 2000
94. S.J. Lanspa, J.X. Jenkins, R.J. Cavalieri, and et al. Surveillance in Lynch syndrome: how aggressive? Am J Gastroenterol 89 1994 1978 1980
95. D.L. Edelstein, J. Axilbund, M. Baxter, and et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome Clin Gastroenterol Hepatol 9 2011 340 343
96. A.E. de Jong, F.M. Nagengast, J.H. Kleibeuker, and et al. What is the appropriate screening protocol in Lynch syndrome? Fam Cancer 5 2006 373 378
97. J.F. Haanstra, H.F. Vasen, S. Sanduleanu, and et al. Quality colonoscopy and risk of interval cancer in Lynch syndrome Int J Colorectal Dis 28 2013 1643 1649
98. H.F. Vasen, M. Abdirahman, R. Brohet, and et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome Gastroenterology 138 2010 2300 2306
99. W.H. de Vos tot Nederveen Cappel, F.M. Nagengast, G. Griffioen, and et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families Dis Colon Rectum 45 2002 1588 1594
100. H.J. Jarvinen, L. Renkonen-Sinisalo, K. Aktan-Collan, and et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members J Clin Oncol 27 2009 4793 4797
101. H.F. Vasen, M. van Ballegooijen, E. Buskens, and et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers Cancer 82 1998 1632 1637
102. A.T. Chan, N. Arber, J. Burn, and et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview Cancer Prev Res 5 2012 164 178
103. J. Burn, D.T. Bishop, J.P. Mecklin, and et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome N Engl J Med 359 2008 2567 2578
104. J. Burn, A.M. Gerdes, F. Macrae, and et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial Lancet 378 2011 2081 2087
105. F. Balaguer, J. Balmana, S. Castellvi-Bel, and et al. Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients Gastroenterology 134 2008 39 46
106. R.C. Green, P.S. Parfrey, M.O. Woods, and et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer J Natl Cancer Inst 101 2009 331 340
107. R.C. Mercado, H. Hampel, F. Kastrinos, and et al. Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases Genet Med 14 2012 670 680
108. E.M. Monteiro Santos, M.D. Valentin, F. Carneiro, and et al. Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries BMC Cancer 12 2012 64
109. C. Tresallet, A. Brouquet, C. Julie, and et al. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome Int J Cancer 130 2012 1367 1377
110. F.J. Backes, H. Hampel, K.A. Backes, and et al. Are prediction models for Lynch syndrome valid for probands with endometrial cancer? Fam Cancer 8 2009 483 487
111. B.V. Bapat, L. Madlensky, L.K. Temple, and et al. Family history characteristics, tumor microsatellite instability and germline MSH2 and MLH1 mutations in hereditary colorectal cancer Hum Genet 104 1999 167 176
112. T. Caldes, J. Godino, A. Sanchez, and et al. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer Oncol Rep 12 2004 621 629
113. M. Christensen, N. Katballe, F. Wikman, and et al. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing Cancer 95 2002 2422 2430
114. B. Dieumegard, S. Grandjouan, J.C. Sabourin, and et al. Extensive molecular screening for hereditary non-polyposis colorectal cancer Br J Cancer 82 2000 871 880
115. C. Durno, M. Aronson, B. Bapat, and et al. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma Gut 54 2005 1146 1150
116. S.M. Farrington, J. Lin-Goerke, J. Ling, and et al. Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls Am J Hum Genet 63 1998 749 759
117. Y. Hendriks, P. Franken, J.W. Dierssen, and et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors Am J Pathol 162 2003 469 477
118. R. Hoedema, T. Monroe, C. Bos, and et al. Genetic testing for hereditary nonpolyposis colorectal cancer Am Surg 69 2003 387 391 discussion 391-392
119. N. Katballe, M. Christensen, F.P. Wikman, and et al. Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients Gut 50 2002 43 51
120. C. Lamberti, R. Kruse, C. Ruelfs, and et al. Microsatellite instability-a useful diagnostic tool to select patients at high risk for hereditary non-polyposis colorectal cancer: a study in different groups of patients with colorectal cancer Gut 44 1999 839 843
121. S.C. Lee, J.Y. Guo, R. Lim, and et al. Clinical and molecular characteristics of hereditary non-polyposis colorectal cancer families in Southeast Asia Clin Genet 68 2005 137 145
122. P.J. Limburg, W.S. Harmsen, H.H. Chen, and et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer Clin Gastroenterol Hepatol 9 2011 497 502
123. T. Liu, S. Wahlberg, E. Burek, and et al. Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer Genes Chromosomes Cancer 27 2000 17 25
124. G. Moslein, D.J. Tester, N.M. Lindor, and et al. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer Hum Mol Genet 5 1996 1245 1252
125. R.C. Niessen, M.J. Berends, Y. Wu, and et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer Gut 55 2006 1781 1788
126. H. Okkels, K. Lindorff-Larsen, O. Thorlasius-Ussing, and et al. MSH6 mutations are frequent in hereditary nonpolyposis colorectal cancer families with normal pMSH6 expression as detected by immunohistochemistry Appl Immunohistochem Mol Morphol 20 2012 470 477
127. D.J. Peel, A. Ziogas, E.A. Fox, and et al. Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases J Natl Cancer Inst 92 2000 1517 1522
128. J. Plaschke, C. Engel, S. Kruger, and et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium J Clin Oncol 22 2004 4486 4494
129. P. Plevova, A. Krepelova, M. Papezova, and et al. Immunohistochemical detection of the hMLH1 and hMSH2 proteins in hereditary non-polyposis colon cancer and sporadic colon cancer Neoplasma 51 2004 275 284
130. S. Salahshor, K. Koelble, C. Rubio, and et al. Microsatellite Instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer Lab Invest 81 2001 535 541
131. M. Scartozzi, F. Bianchi, S. Rosati, and et al. Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression J Clin Oncol 20 2002 1203 1208
132. J. Shia, D.S. Klimstra, K. Nafa, and et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms Am J Surg Pathol 29 2005 96 104
133. M. Spaepen, B. Vankeirsbilck, S. Van Opstal, and et al. Germline mutations of the hMLH1 and hMSH2 mismatch repair genes in Belgian hereditary nonpolyposis colon cancer (HNPCC) patients Fam Cancer 5 2006 179 189
134. J.G. Stone, D. Robertson, and R.S. Houlston Immunohistochemistry for MSH2 and MHL1: a method for identifying mismatch repair deficient colorectal cancer J Clin Pathol 54 2001 484 487
135. A.T. Stormorken, I.M. Bowitz-Lothe, T. Noren, and et al. Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer J Clin Oncol 23 2005 4705 4712
136. S.N. Thibodeau, A.J. French, P.C. Roche, and et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes Cancer Res 56 1996 4836 4840
137. S.S. Wahlberg, J. Schmeits, G. Thomas, and et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families Cancer Res 62 2002 3485 3492
138. J. Wang, M.H. Luo, Z.X. Zhang, and et al. Clinical and molecular analysis of hereditary non-polyposis colorectal cancer in Chinese colorectal cancer patients World J Gastroenterol 13 2007 1612 1617
139. B. Wolf, S. Gruber, S. Henglmueller, and et al. Efficiency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in Austrian HNPCC patients Int J Cancer 118 2006 1465 1470
140. A. Alemayehu, K. Sebova, and I. Fridrichova Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients Genes Chromosomes Cancer 47 2008 906 914
141. G. Berginc, M. Bracko, M. Ravnik-Glavac, and D. Glavac Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome Fam Cancer 8 2009 421 429
142. H. Bouzourene, P. Hutter, L. Losi, and et al. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation Fam Cancer 9 2010 167 172
143. G. Canard, J.H. Lefevre, C. Colas, and et al. Screening for Lynch syndrome in colorectal cancer: are we doing enough? Ann Surg Oncol 19 2012 809 816
144. E. Domingo, P. Laiho, M. Ollikainen, and et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing J Med Genet 41 2004 664 668
145. J. Ewald, C.M. Rodrigue, N. Mourra, and et al. Immunohistochemical staining for mismatch repair proteins, and its relevance in the diagnosis of hereditary non-polyposis colorectal cancer Br J Surg 94 2007 1020 1027
146. C. Julie, C. Tresallet, A. Brouquet, and et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening Am J Gastroenterol 103 2008 2825 2835 quiz 2836
147. S.A. Kuismanen, M.T. Holmberg, R. Salovaara, and et al. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers Am J Pathol 156 2000 1773 1779
148. N. Lubomierski, G. Plotz, M. Wormek, and et al. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors Cancer 104 2005 952 961
149. A. McGivern, C.V. Wynter, V.L. Whitehall, and et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer Fam Cancer 3 2004 101 107
150. M. Menigatti, C. Di Gregorio, F. Borghi, and et al. Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer Genes Chromosomes Cancer 31 2001 357 361
151. J.N. Poynter, K.D. Siegmund, D.J. Weisenberger, and et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening Cancer Epidemiol Biomarkers Prev 17 2008 3208 3215
152. N. Rahner, N. Friedrichs, V. Steinke, and et al. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome J Pathol 214 2008 10 16
153. A. Thiel, M. Heinonen, J. Kantonen, and et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome Virchows Arch 463 2013 613 621
154. R.L. Ward, S. Hicks, and N.J. Hawkins Population-based molecular screening for Lynch syndrome: implications for personalized medicine J Clin Oncol 31 2013 2554 2562
155. J.M. Wheeler, A. Loukola, L.A. Aaltonen, and et al. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers J Med Genet 37 2000 588 592
156. H. Yamamoto, Y. Min, F. Itoh, and et al. Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high-frequency microsatellite instability Genes Chromosomes Cancer 33 2002 322 325
157. M. Yearsley, H. Hampel, A. Lehman, and et al. Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter Hum Pathol 37 2006 831 838
158. E. Barrow, E. Jagger, J. Brierley, and et al. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome Histopathology 56 2010 331 344
159. D. Calistri, S. Presciuttini, G. Buonsanti, and et al. Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition Int J Cancer 89 2000 87 91
160. A. Paya, C. Alenda, L. Perez-Carbonell, and et al. Utility of p16 immunohistochemistry for the identification of Lynch syndrome Clin Cancer Res 15 2009 3156 3162